PRA Health Sciences pioneers connecting clinical trial patients with their real-world data with Synoma
Pharmaceutical, biotech and other research sponsors can now connect their clinical studies to longitudinal real-world data – speeding up drug development and aligning with the 21st Century Cures Act.
RALEIGH, N.C., May 13, 2021 (GLOBE NEWSWIRE) PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today an innovative tokenization solution using Synoma
®, PRA’s proprietary technology that allows for the generation of enhanced evidence for drug development. PRA’s solution makes it possible to connect clinical trial data and secondary data sets with privacy at the forefront. Today, three large pharmaceutical companies, along with several other pharmaceutical and biotech companies of all sizes, are using Synoma to link data and conduct analyses across their drug development portfolios.
NEW YORK, May 14, 2021 /PRNewswire/ PM360, the premier information resource for marketing decision makers in the pharmaceutical, biotech, diagnostics, and medical device sectors, today announced the winners of
13 may 2021
PRA Health Sciences pioneers connecting clinical trial patients with their real-world data with Synoma
Pharmaceutical, biotech and other research sponsors can now connect their clinical studies to longitudinal real-world data – speeding up drug development and aligning with the 21st Century Cures Act.
RALEIGH, N.C., May 13, 2021 (GLOBE NEWSWIRE) PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today an innovative tokenization solution using Synoma
®, PRA’s proprietary technology that allows for the generation of enhanced evidence for drug development. PRA’s solution makes it possible to connect clinical trial data and secondary data sets with privacy at the forefront. Today, three large pharmaceutical companies, along with several other pharmaceutical and biotech companies of all sizes, are using Synoma to link data and conduct analyses across their drug development portfolios.
Home / Press Release / PRA’s remote patient monitoring platform selected by Merck KGaA, Darmstadt, Germany to work in combination with its human growth hormone treatment system
PRA’s remote patient monitoring platform selected by Merck KGaA, Darmstadt, Germany to work in combination with its human growth hormone treatment system
PRA’s cloud-based infrastructure enables Merck KGaA, Darmstadt, Germany to deliver a better product experience and scale for future enhancements
RALEIGH, N.C. , April 07, 2021 (GLOBE NEWSWIRE) PRA Health Sciences (NASDAQ: PRAH) announced today that Merck KGaA, Darmstadt, Germany, known in the United States as EMD Serono, selected PRA’s remote patient monitoring platform to work in combination with its human growth hormone (HGH) treatment system. Under this agreement, PRA’s remote patient monitoring platform backs Merck KGaA, Darmstadt, Germany’s HGH treatment system, including growlink